In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
• By Wendy Diller
The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
